|
|
|
|
Gain insight into how antibody-drug conjugate (ADC) chemistry and manufacturing have evolved over the past fifteen years, the challenges this dynamic growth has created, and how CDMOs are adapting to these changes to meet customer needs, now and in the future.
|
|
|
|
|
Streamlining antibody-drug conjugate development through an integrated CDMO can reduce risk and improve quality. Explore why specialized expertise in linker chemistry and bioconjugation is key to overcoming the complexity of ADC manufacturing.
|
|
|
|
|
ADCs represent a breakthrough in cancer treatment by combining the targeting power of antibodies with the potency of cytotoxic drugs. Learn how this method minimizes harm to healthy tissue and revolutionizes treatment for cancer.
|
|
|
|
|
|
|
|
ADC & BIOCONJUGATION CDMO SERVICES
|
|
|
|
|
Antibody-drug conjugates (ADCs) have ignited a new era of targeted cancer therapies but there are several obstacles and complexities to overcome to bring these therapies to market. To solve the challenges and ensure success of your ADC project, you can rely on an industry-leading CDMO partner with 15+ years experience and focused expertise to meet your ADC development and manufacturing needs, from pre-clinical to commercial. Learn more.
|
|
|
